Printer Friendly

Ayala Pharmaceuticals to Develop and Commercialise AL102 in Combination with BCMA Targeting Agents in Multiple Myeloma.

M2 PHARMA-December 26, 2018-Ayala Pharmaceuticals to Develop and Commercialise AL102 in Combination with BCMA Targeting Agents in Multiple Myeloma

(C)2018 M2 COMMUNICATIONS

- Israel-based clinical-stage company Ayala Pharmaceuticals, Inc has entered into an option to license agreement with Swiss pharmaceutical company Novartis' (SIX: NOVN) (NYSE: NVS) for its investigational agent AL102 in multiple myeloma, the company said.

Under the terms of the deal, Ayala will receive a USD 10m equity investment from Novartis and is eligible to receive development, clinical, regulatory and commercial milestones along with tiered royalties on net sales of AL102.

Novartis will conduct certain studies to evaluate AL102 in combination with its B-cell maturation antigen therapies in multiple myeloma. Ayala will provide the drug supply.

All development costs associated with the above studies will be fully born by Novartis. Ayala retains worldwide license rights for AL102 for all other indications.

AL102 is an oral small-molecule that inhibits gamma secretase, an enzyme which may be targeted to increase levels of BCMA, which is expressed in most multiple myeloma patients.

BCMA is actively shed from multiple myeloma cells by gamma secretase, hence its inhibition by AL102 may increase BCMA levels on multiple myeloma cells.

Therefore, AL102 is being studied to evaluate its clinical role in enhancing anti-BCMA therapies.

Ayala is committed to developing new targeted therapies for genomically-defined cancers in patient populations with high unmet medical need.

In addition to investigating AL102 as an anti-BMCA therapy in multiple myeloma, Ayala is evaluating AL102 as an inhibitor of the Notch pathway in other hematologic cancers.

Multiple myeloma is a rare and aggressive blood cancer that accounts for approximately one % of all cancers.

In the US, there are nearly 90,000 people living with, or in remission from, multiple myeloma. Approximately, 26,850 Americans are diagnosed with multiple myeloma each year and 11,240 patient deaths are reported on an annual basis.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers.

The company is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and nonclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102).

The company's lead agent, AL101, is currently in Phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations.

As a precision oncology company, Ayala was founded in November 2017 with an experienced global management team and a strong investor base.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 26, 2018
Words:415
Previous Article:Janssen Announces European Commission Approval of Darzalex Split Dosing Regimen.
Next Article:Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters